Anastrozole

Introduction Overview

Generic Name

anastrozole

Brand Name

Arimidex

Dosage Form

oral tablet

Drug Class

Aromatase inhibitor, Hormones / antineoplastics

Pharmacokinetics

Absorption

Anastrozole is well absorbed orally with bioavailability approaching nearly 100%, indicating minimal first-pass metabolism. Peak plasma concentrations are typically reached within 2 hours post-administration. The absorption of anastrozole is not significantly affected by food, allowing flexible dosing with or without meals. Due to its high oral bioavailability, consistent plasma levels can be achieved with once-daily dosing, enhancing patient compliance.

Distribution

Following absorption, anastrozole is widely distributed throughout the body tissues. It exhibits a volume of distribution ranging approximately from 40 to 50 L, reflective of extensive tissue penetration. Plasma protein binding is moderate, about 40%, primarily to albumin, facilitating both free and bound drug circulating in plasma. The drug crosses cellular membranes readily, targeting estrogen-producing tissues such as breast tumor sites.

Metabolism

Anastrozole undergoes extensive hepatic metabolism primarily through N-dealkylation, hydroxylation, and glucuronidation processes mediated by cytochrome P450 enzymes, notably CYP3A4. The metabolites formed are pharmacologically inactive. The metabolic pathways help in reducing active drug concentrations and facilitate excretion. The metabolism is not subject to significant first-pass effect and demonstrates linear pharmacokinetics over the therapeutic dose range.

Elimination

Elimination of anastrozole and its metabolites occurs mainly via renal excretion, accounting for approximately 70% of the administered dose. Fecal excretion constitutes around 10-20%. The terminal half-life is approximately 50 hours, allowing for steady-state concentrations to be reached in about 7 days with once-daily dosing. Renal or hepatic impairments may moderately affect clearance; therefore, monitoring in such populations is advised.

Dosage Forms

Adults

The recommended adult dosage for Arimidex is 1 mg orally once daily. Therapy duration typically extends up to 5 years depending on clinical indication and patient response. It is utilized in adjuvant treatment of hormone receptor-positive early breast cancer, first-line therapy for locally advanced or metastatic breast cancer, and second-line therapy following tamoxifen failure.

Adolescents

Arimidex is not indicated for use in adolescents or pediatric populations. Safety and efficacy in this group have not been established, and it is approved solely for postmenopausal women.

Special Populations

Postmenopausal women are the sole approved population. Patients with renal impairment do not require dosage adjustment, but caution is advised with severe hepatic dysfunction. Not for use in premenopausal women, men, or during pregnancy and breastfeeding. Use in patients with osteoporosis or history of fractures warrants monitoring bone mineral density and prophylactic measures to maintain bone health.

Mechanism Of Action

Anastrozole, marketed as Arimidex, functions as a potent, selective, non-steroidal aromatase inhibitor. Aromatase (CYP19) is a cytochrome P450 enzyme complex responsible for the peripheral conversion of androgens (androstenedione and testosterone) into estrogens (estrone and estradiol) in postmenopausal women. By inhibiting aromatase, anastrozole effectively suppresses circulating estrogen levels, leading to decreased stimulation of estrogen-dependent breast cancer cells, thereby inhibiting tumor growth.

This inhibition occurs by competitive binding to the heme moiety of aromatase, blocking its enzymatic activity without affecting other steroidogenic pathways significantly. The profound suppression of serum estradiol levels by approximately 80-90% reduces estrogen-mediated proliferation signaling in hormone receptor-positive breast cancer cells. This mechanism underpins its clinical efficacy in both adjuvant and metastatic settings in postmenopausal women.

Anastrozole's action contrasts with selective estrogen receptor modulators like tamoxifen, which block estrogen receptors but do not reduce systemic estrogen. By removing the ligand itself, anastrozole provides a unique endocrine therapy modality. Clinical studies have demonstrated improved disease-free survival and reduced recurrence rates with anastrozole compared to tamoxifen in many cases. Research continues to explore its molecular interactions and potential resistance mechanisms involving upregulation of alternative growth pathways.

Pharmacological Actions

Potent, selective inhibition of aromatase enzyme leading to decreased estrogen synthesis
Significant reduction in circulating estradiol and estrone levels in postmenopausal women
Suppression of estrogen-dependent tumor cell proliferation
Lack of agonist or partial agonist activity at estrogen receptors
Exhibits anti-proliferative effects in hormone receptor-positive breast cancer
Does not interfere with progesterone or androgen receptor pathways
Demonstrates longer half-life enabling once-daily dosing
Minimal off-target effects due to enzyme selectivity
No significant pro-thrombotic activity compared to other hormonal therapies
Does not induce cytochrome P450 enzymes substantially

Therapeutic Clinical Uses

Adjuvant treatment for hormone receptor-positive early breast cancer in postmenopausal women
First-line treatment for hormone receptor-positive or unknown locally advanced or metastatic breast cancer in postmenopausal women
Second-line treatment for advanced breast cancer after progression on tamoxifen therapy
Off-label use in metastatic breast cancer when estrogen suppression is beneficial
Potential use in combination regimens with targeted therapies in resistant breast cancer forms
Endocrine therapy in hormone receptor-positive breast malignancies to reduce recurrence risk
Treatment of breast cancer patients intolerant to other hormonal therapies

Side Or Adverse Effects

Hot flashes and vasomotor symptoms
Joint pain, stiffness, and arthralgia leading to decreased mobility
Bone pain and increased risk of osteoporosis-related fractures
Fatigue and generalized weakness
Nausea and occasional vomiting
Headache and dizziness
Swelling of extremities (edema)
Depression, mood swings, and insomnia
Increased blood pressure (hypertension)
Rash and skin reactions including dryness
Symptoms of bone fracture such as bruising and localized tenderness
Shortness of breath and respiratory symptoms like cough
Potential elevation of liver enzymes indicating hepatotoxicity
Rare severe allergic reactions including hives and swelling
Increased risk of cardiovascular events such as stroke and thrombosis

Precautions

Use cautiously in patients with history of coronary artery disease due to risk of decreased cardiac blood flow
Monitor bone mineral density regularly as aromatase inhibition can weaken bones
Avoid concomitant use with tamoxifen to prevent antagonistic effects
Pregnancy must be excluded before initiation due to fetal harm risk
Not recommended during breastfeeding and requires discontinuation prior to nursing
Caution in patients with hyperlipidemia or osteoporosis
Assess hepatic and renal function before and during treatment
Advise patients about potential for mood changes and report psychiatric symptoms
Advise on the importance of adherence due to long-term treatment duration
Avoid estrogen-containing medications as they may reduce Arimidex efficacy
Monitor for signs of stroke or thromboembolism especially in high-risk patients
Consider calcium and vitamin D supplementation for bone health during therapy

Warnings

Potential to decrease coronary blood flow; new or worsening chest pain requires urgent evaluation
Increased risk of thromboembolic events including stroke; sudden neurological symptoms need immediate attention
Contraindicated during pregnancy due to teratogenicity
Not recommended for premenopausal women as it may impair ovarian function without benefit
May reduce bone mineral density increasing fracture risk; bone health should be closely monitored
Avoid use with estrogen therapies due to diminished therapeutic effect
Risk of severe allergic reactions and serious skin reactions
Use with caution in patients with hepatic impairment
Potential for hypertension development or worsening during therapy
Long-term safety beyond 5 years is not well established

Contraindications

Known hypersensitivity to anastrozole or any component of the formulation
Pregnancy: anastrozole can cause fetal harm
Pre-menopausal women, including female children and adolescents
Concomitant use with tamoxifen or other estrogen-containing therapies
Patients with severe hepatic impairment without clinical monitoring capability
Breastfeeding mothers
Patients with uncontrolled cardiovascular disease
Known osteoporosis without appropriate management plan
Hypersensitivity reactions to aromatase inhibitors previously experienced

Drug Interactions

Estrogen-containing products (hormone replacement therapy, estrogen creams, birth control pills, patches) reduce anastrozole efficacy
Tamoxifen: antagonistic interaction contraindicated concomitantly
Certain CYP3A4 inhibitors or inducers may alter anastrozole metabolism theoretically but clinical significance is limited
Corticosteroids: concomitant use may increase osteoporosis risk
Anticoagulants require monitoring due to potential altered coagulation balance
Drugs affecting bone metabolism like bisphosphonates may be co-administered with caution
Concomitant use with diuretics requires monitoring for fluid balance changes
Potential interaction with herbal supplements affecting estrogen pathways (e.g., black cohosh)
No significant interaction with common chemotherapy agents documented
Interactions with other CYP450 substrates are minimal but patient monitoring advised
Use caution with other drugs causing QT prolongation although direct link not established

Preparations Of The Drug

Oral tablet formulation containing 1 mg anastrozole
Available as single-dose blister packs or bottles for daily administration
Generic and brand versions available for prescription
Tablets are film-coated, white or off-white, round
Available in packaging containing 30 tablets for one month’s therapy
Stable at room temperature away from moisture and heat
Oral route preferred due to consistent absorption and ease of use
No injectable or topical forms commercially available